Lenacapavir
Lenacapavir (development code GS-6207) is an experimental drug for the treatment of HIV being developed by Gilead Sciences. As of 2021, it is in Phase 2/3 clinical trials. It is being investigated as a treatment for HIV patients infected with multidrug-resistant virus and as a twice-yearly injectable for pre-exposure prophylaxis (PrEP). If successful in clinical trials, it would become a first-in-class HIV capsid inhibitor for the treatment of HIV.